Clinical Takeaway
A significant portion of individuals diagnosed with cannabis-induced psychosis will later develop a primary psychiatric disorder such as schizophrenia spectrum disorder or bipolar disorder. Clinicians should treat a cannabis-induced psychosis episode as a serious warning sign requiring close follow-up and long-term monitoring rather than a self-limiting event. Early identification and structured follow-up care may be critical in preventing or mitigating the progression to a chronic psychiatric condition.
#24 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Citation: Javed Mohammad Saad et al.. Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.. BMC psychiatry. 2026. PMID: 41664079.
Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical diagnostic challenge in clinical psychiatry by quantifying the risk that patients with cannabis-induced psychosis will subsequently develop schizophrenia spectrum or bipolar disorder, information essential for prognostic counseling and treatment planning. Understanding this progression rate helps clinicians distinguish transient cannabis-related psychotic episodes from prodromal presentations of primary psychiatric disorders, which carries substantial implications for long-term pharmacological management and patient outcomes. The findings establish an evidence-based foundation for developing standardized clinical guidelines in a treatment area currently lacking consensus protocols.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.
🧠 This meta-analysis addresses a clinically important question: what proportion of patients presenting with cannabis-induced psychosis subsequently develop schizophrenia spectrum or bipolar disorder? While the pooled prevalence data will help quantify transition risk, clinicians should note several important confounders that likely influence these estimates, including variable diagnostic criteria across studies, heterogeneous follow-up periods, differences in cannabis potency and use patterns over time, and the inherent difficulty in distinguishing primary versus substance-induced psychosis at initial presentation. The quality and methodology of included studies will substantially affect the robustness of any meta-analytic conclusion, and publication bias toward positive transitions cannot be excluded. From a practical standpoint, these findings should inform risk stratification and counseling rather than deterministic predictions: a patient with cannabis-induced psychosis warrants careful longitudinal psychiatric follow-up and assessment for prodromal features or family history of psychotic or mood disorders, but cannabis use alone should not be assumed to inevitably trigger primary psychiatric illness in every individual